Vialon M, Grunenwald S, Mouly C, et al. - In this single-centre experience of 14 pregnancies, researchers assessed the prevalence of gestational diabetes (GD) in acromegalic women submitted to a systematic screening for GD and then compared women with or without GD. Fourteen pregnancies in 11 women (34.0 ± 3.6 years) treated with somatostatin analogues after a pituitary surgery (n = 6) or as primary (n = 5) therapy were studied, and treatment was stopped at the time of pregnancy diagnosis for 13 pregnancies. During pregnancy, one woman was diagnosed with acromegaly and was treated with octreotide LAR between 12 and 18 weeks of gestation. According to fasting blood glucose (n = 5) or to an oral glucose tolerance test (n = 2), GD was diagnosed during 7 pregnancies in 6 women (one woman had GD during her 2 pregnancies). IGF-1 was not controlled in 4 GD+ and in 2 GD− women before pregnancy. Women's prevalence of GD is higher than that reported in the literature, likely resulting from the systematic screening of GD and women's age. Therefore, routine GD screening should be considered in women with acromegaly, particularly those with GD risk factors and prepregnancy uncontrolled levels of IGF-1.